COMP <GO>
RLMD vs SPRY // EV/EBITDA & P/E VALUATION
Relmada Therapeutics Inc. (NASDAQ) VS. ARS Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: RLMD 2
— SPRY 1
■ METRIC PARITY
LAST: $3.44 (+2.69%) • MKT CAP: $366.9M
valuation
—
LAST: $3.66 (+0.27%) • MKT CAP: $364.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLMD VS. SPRY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RLMD | SPRY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.48% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -5.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | SPRY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.9 | 29.8 | +23.12 | RLMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $366.9M | $364.0M | $3.0M | RLMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RLMD REV | SPRY REV | RLMD GROSS % | SPRY GROSS % | RLMD FCF | SPRY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $84.3M | — | — | -$45.8M | -$171.2M |
| FY 2024 | $0 | $89.1M | — | — | -$51.8M | $13.0M |
| FY 2023 | — | $30.0K | — | — | — | -$59.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLMD // BETA —
SPRY // BETA —